A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC

NCT07510594 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Large-Cell Neuroendocrine Carcinoma of the Lung
Extrapulmonary Neuroendocrine Carcinoma

Interventions

DRUG: Benmelstobart+ Anlotinib+ Platinum + Etoposide

Sponsor

Tianjin Medical University Cancer Institute and Hospital